# Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

> **NCT05522660** · PHASE3 · RECRUITING · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 180 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Melanoma

## Interventions

- **RADIATION:** Stereotactic radiosurgery
- **DRUG:** Immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT05522660
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-30
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522660, "Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05522660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*